Pharma & Biotech Global Week in Review 9 June 2010 from IP Think Tank

Here is Think IP Strategy’s weekly selection of top Pharma & Biotech intellectual property news breaking in the blogosphere and internet.

Please join the discussion by adding your comments on any of these stories, and please do let us know if you think we’ve missed something important, or if there is a source you think should be monitored.

You can separately subscribe to the IP Think Tank Global Week in Review at the Subscribe page: http://thinkipstrategy.com/subscribe/

Highlights this week included:

US: Biogen launches submarine patent against competing providers of Interferon-Beta products (Holman’s Biotech IP Blog)(Patent Docs) (Patent Docs)

General

Drug access waiver debate looms for June TRIPS Council Meeting (IP Watch)

Worning named acting head of WHO IP Division (IP Watch)

Australian Senate to release gene patenting findings next week (Patent Docs)

EU generics producers’ plan for market access (IP Watch)

Poland: Reading comprehension – pharmaceutical labelling (Class 46)

UK: Account of profits against non-combatant defendants: Pfizer Incorporated v Mills and others (IP finance)

US: AMP v. USPTO: What everyone else is saying – Part II (Patent Docs)

US: Jackson Labs doesn’t infringe after patent discloses but does not claim mouse: Central Institute for Experimental Animals v. Jackson Labs (Patent Baristas)

US: Complaint filed for review and correction of the patent term adjustment calculation: Magnachem International Laboratories, Inc. v. Kappos (Patent Docs)

Products

Allegra (Fexofenadine) – US: Patent infringement complaint following a Paragraph IV certification: Sanofi-Aventis U.S. LLC et al. v. Actavis Inc. et al. (Patent Docs)

Angiomax(Bivalirudin) – US: Patent infringement complaint following a Paragraph IV certification Medicines Co. v. APP Pharmaceuticals LLC et al. (Patent Docs)

Avonex (Interferon) – US: Biogen launches submarine patent against competing providers of Interferon-Beta products: Biogen Idec MA Inc. v. EMD Serono, Inc. et al. (Holman’s Biotech IP Blog)(Patent Docs) (Patent Docs)

Cenestin (Conjugated estrogens) US: Teva’s patent for Cenestin under threat due to file wrapper estoppel (IP Factor)

Cipro (Ciprofloxacin) – US: Court of Appeals for the Second Circuit invites examination of reverse settlement agreements by the Full Court of Appeals (IP Whiteboard)

Combivir (Lamivudine, Zidovudine) – US: GlaxoSmithKline and Teva reach settlement in Combivir dispute (Patent Docs)

Cubicin (Daptomycin) – US: Cubist Pharmaceuticals receives claim construction order in patent infringement action against Teva Parenteral Medicines, Inc. (SmartBrief)

Emend (Aprepitant) – US: Sandoz counterclaims for two patents dismissed in Merck’s Emend suit (Patent Docs)

Intuniv (Guanfacine) – US: Patent infringement complaint based on ANDA filing: Shire LLC et al. v. Anchen Pharmaceuticals Inc. et al. (Patent Docs)

Monistat 1 (Miconazole)- US: A new 180-day exclusivity punt – but don’t read too much into it (FDA Law Blog)

Nexterone (Amiodarone HCI) – US: Is another challenge to the PTO’s PTE ‘Product’ interpretation looming? (FDA Law Blog)

Opana (Oxymorphone) – US: Impax Laboratories and Endo Pharmaceuticals settle pending litigation for Opana ER and announce development and co-promotion agreement (SmartBrief) (SmartBrief) (SmartBrief)

Prandin (Repaglinide) – US: Patent infringement complaint following a Paragraph IV certification: Novo Nordisk Inc. et al. v. Paddock Laboratories, Inc. (Patent Docs)

Sitagliptin – Germany: Federal Patent Court referral concerning SPCs: C-125/10 – Merck & Co Inc v Deutsche Patent- und Markenamt (The SPC blog)

Thalomid (Thalidomide) – US: Celgene, Barr resolve patent dispute over generic Thalomid (Patent Docs)

Ultram (Tramadol) – US: Pharma Products L.P. v. Par Pharmaceutical, Inc. (Fed. Cir. 2010) – Further adventures in obviousness and inequitable conduct (Patent Docs)

Viagra (Sildenafil) – Australia: You had me at Viagra – Pfizer successfully opposes VIAGUARA for alcoholic beverages (IP Whiteboard)

Yaz (Drospirenone & Ethinyl Estradiol) – US: Patent infringement complaint / application for declaratory judgment of noninfringment Bayer Schering et al. v. Teva et al.; Teva et al. v. Bayer Schering et al. (Patent Docs)

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: